What Is the Starting Dose of Compounded Tirzepatide?

There is a clean answer to “what is the starting dose of tirzepatide” and a messier answer to “what is the starting dose of compounded tirzepatide.” The clean one comes from the trials: in the pivotal obesity study, participants began at 2.5 mg once weekly and stayed there for four weeks before any increase^[1]. The messier one is that a compounded preparation has no approved labeling of its own. Whatever schedule your provider uses is inherited from the brand evidence, not established for the product in your hand — and the vial's concentration determines how that milligram figure becomes a number on a syringe^[3].

The schedule the evidence actually supports

The obesity trial that established tirzepatide's weight-loss profile started every participant at the same low dose regardless of the target they were randomized to, then escalated in 2.5 mg steps at four-week intervals until the assigned dose was reached^[1]. That structure is deliberate: the starting dose is not a therapeutic dose. It exists to let the gastrointestinal tract adapt before the dose that does the work arrives.

Two features of that table are worth stating plainly. Escalation is stepwise and time-bound — the interval is as much a part of the schedule as the increment. And the starting dose is explicitly a run-in: someone who stops at 2.5 mg has not had a low-dose course of treatment, they have had the adaptation period without the treatment.

Why titration exists at all

Tirzepatide slows gastric emptying and acts on appetite pathways, and the resulting nausea, vomiting and other gastrointestinal effects are dose-related and most pronounced when the dose changes. Starting low and stepping up gives those effects time to attenuate at each level. Its pharmacokinetics make the four-week interval sensible rather than arbitrary: population modeling supports once-weekly dosing^[2], and it takes several weekly doses at a new level to approach steady state — so escalating faster means escalating before you have seen what the current dose actually does.

What changes when the product is compounded

• The schedule is borrowed, not approved. A compounded vial carries no FDA-approved dosing labeling. If a provider uses the 2.5 mg start and four-week steps, they are applying the brand evidence to a different preparation — reasonable, but it is an extrapolation and worth recognizing as one.
• Milligrams stay constant; units do not. Your prescribed dose is in milligrams. What you draw depends on the vial's concentration, so the same 2.5 mg is 25 units from one vial and 12.5 from another. A new vial at a new concentration silently changes the correct syringe reading. See our units conversion article for the arithmetic.
• Non-standard starting doses appear in this market. Some providers begin below 2.5 mg. That is not the schedule the pivotal trial tested, which does not automatically make it wrong — but it does mean the efficacy data do not describe it, and it is fair to ask what the reasoning is.
• The measurement error is a dosing error. The documented harm at initiation is not usually a wrong prescription — it is a correct prescription measured on the wrong scale. A poison control case series recorded exactly this pattern with compounded GLP-1 vials^[3].
• Product consistency is not guaranteed between batches. Analysis of follow-on and compounded GLP-1 receptor agonists has examined their impurity profiles and potential immunogenicity^[4], so “same molecule” does not by itself mean “same product each time.”

Questions worth asking at the start

1. What is my dose in milligrams, and what is the concentration of this vial in mg per mL? Both numbers, before the first injection.
2. How many units does that work out to on the syringe I have been given — and does the arithmetic check out when I do it myself?
3. How long do I stay at this dose before any change, and who decides?
4. What should I do if the gastrointestinal effects are severe — hold, slow down, or stop?
5. If my next vial has a different concentration, how will I be told?